News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Email Alerts

Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go

Advanced Search

Keywords

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Oct 22, 2009

  Insmed To Host Third Quarter 2009 Conference Call
• Sep 16, 2009

  Insmed Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price
• Aug 13, 2009

  Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009
• Jul 31, 2009

  Insmed to Host Second Quarter 2009 Conference Call
• Jul 27, 2009

  Insmed Provides Update on Supply of IPLEX(TM)
• Jun 30, 2009

  Insmed Announces Addition to the Russell 3000(R) Index
• Jun 25, 2009

  Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
• Jun 15, 2009

  Insmed CEO Resigns Due to Health Concerns
• May 13, 2009

  Insmed Announces First Quarter 2009 Financial Results
• May 5, 2009

  Insmed Regains NASDAQ Compliance
• Apr 23, 2009

  Insmed to Host First Quarter 2009 Conference Call
• Apr 22, 2009

  Insmed to Host First Quarter 2009 Conference Call
• Mar 31, 2009

  Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
• Mar 30, 2009

  Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
• Mar 25, 2009

  Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
• Mar 11, 2009

  Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
• Mar 10, 2009

  Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND
• Feb 26, 2009

  Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
• Feb 12, 2009

  Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
• Jan 21, 2009

  Insmed and Premacure Announce European Orphan Designation for IPLEX(TM) in Retinopathy of Prematurity in Infants
• Dec 26, 2008

  Insmed to Appeal Delisting Notification From Nasdaq
• Dec 23, 2008

  Insmed Announces that NASDAQ Extends Temporary Suspension of Minimum Bid Closing Price Rule
• Nov 25, 2008

  Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
• Nov 18, 2008

  Insmed to Participate in Federal Trade Commission Roundtable on Follow-on Biologic Drugs: Framework for Competition and Continued Innovation
• Nov 10, 2008

  Insmed Gains Royalty-Free Worldwide Rights for IPLEX(TM) in Connection with Potential Expanded Access ALS Programs

Show 5102550100 per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download